All COVID-19 updates and resources can be found on the CF Canada website.

Skip To Content
Volunteer Advocate

Events Calendar

Community Briefing: Trikafta is coming to Canada
November 12, 2020 6:00 pm

JOIN OUR COMMUNITY BRIEFING TO LEARN MORE

Understanding that there is great anticipation around this Trikafta application and what lies ahead, we will be hosting a community briefing this week to respond to questions, explain next steps in the drug approval process and outline our plans to continue to push to get Trikafta into the hands of Canadians as quickly as possible.

Submit your questions:To ensure the briefing is helpful to you, please share your questions in advance to advocacy@cysticfibrosis.ca 

English briefing
Hosted by: Kelly Grover, John Wallenburg and Kim Steele
When: 6-7pm EST Thursday 12th November, 2020
How to access: https://bit.ly/3lkQSEB

 

CELEBRATE WITH US

We'd love to celebrate this moment with you. Share your reaction on social media tagging @CFCanada and include the hashtag #mytrikaftacheer #hooraytrikafta

WHAT LIES AHEAD

We look forward to confirmation that an application has been submitted to Health Canada to bring Trikafta to Canada and are monitoring the Health Canada website closely for this news.

The Federal Minister of Health has publicly committed to fast track Trikafta. This could shorten review and assessment processes by various government bodies, like Health Canada and the Patented Medicine Pricing Review Board (PMPRB), that can take from one to two years to a year or less.

While the application to Health Canada is a critical step, we still face hurdles to get Trikafta into the hands of Canadians who need it now. Rest assured, we won’t stop until that happens.

Stay tuned for next steps that will include turning our sights to the provincial governments, where we’re already pushing for access to all CF modulators through public drug programs. Our work on stopping implementation of the PMPRB guidelines and creating a fast and fair process for rare disease medicines will also continue, so that Canadians with CF don’t have to wait for future game-changing therapies.